ArticleiScience2026
Regional and national burden of six major digestive cancers in Asia, 1990-2023: An analysis of the GBD Study 2023.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Updated pan-Asian analyses capturing divergent digestive cancer trajectories through the COVID-19 era have been lacking. Using Global Burden of Disease 2023 data, we analyzed disability-adjusted life years (DALYs) for 6 digestive cancers across 34 Asian countries and territories from 1990 to 2023, with projections through 2040. Long-term declines in gastric cancer (GC) contrasted with rises in pancreatic cancer (PC) and colorectal cancer (CRC): GC average annual percent changes were -3.49% in East Asia and -3.77% in high-income Asia Pacific, whereas PC increased in South Asia (+1.53%) and Southeast Asia (+1.54%), and CRC rose in Southeast Asia (+1.30%). Notable pandemic-era shifts emerged: East Asian GC reversed from -6.94% in 2017-2020 to +2.04% in 2020-2023, while PC accelerated sharply, reaching +4.19% in East Asia (2020-2023) and +4.46% in South Asia (2015-2023). Absolute DALYs are projected to rise substantially by 2040 across nearly all regions, with South Asian esophageal cancer DALYs increasing from 3.44 to 8.86 million. Even in regions achieving age-standardized rate declines, demographic pressures will drive absolute burden upward.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.